NEW YORK, Dec. 6, 2024 /PRNewswire/ — This December, Mount Sinai Hospital’s Department of Urology, under the leadership of Ash Tewari, MBBS, MCh, FRCS (Hon.), DSc (Hon.), System Chair of Urology at Mount Sinai, invites you to the Sixth International Prostate Cancer Symposium and World Congress of Urologic Oncology—a four-day event that promises to be a landmark gathering for urology and robotic surgery professionals worldwide.
From December 11-14, 2024, leading experts and innovators will convene at Mount Sinai Hospital to explore groundbreaking advancements in research, clinical practices, and surgical techniques. This program offers an unparalleled opportunity for education, collaboration, and innovation in the ever-evolving field of urologic oncology.
Attendees can look forward to a dynamic lineup that includes:
Over 100 global leaders in urologic oncology will share their expertise, including:
This year’s symposium is more than an educational event; it’s a chance to connect with top professionals, engage in thought-provoking discussions, and experience cutting-edge technology. From live surgical demonstrations to holographic presentations by international experts, the program is designed to push the boundaries of urology and robotic surgery.
Don’t miss this opportunity to be part of a global gathering of thought leaders and innovators. Register now to secure your place at this extraordinary event.
For additional details and registration, visit: https://mountsinaiurologycme.com
To relive the excitement, check out highlights from last year’s symposium: https://www.youtube.com/watch?v=iRbrhe5kQ-c
Join us at Mount Sinai Hospital in New York City this December as we shape the future of urology and robotic surgery!
Media Contact: Michael Inocencio, 19143146029, michael.inocencio@mountsinai.org
SOURCE Mount Sinai Hospital
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…